LadRx Corp. Stock Analysis LADX
LadRx Corp. is a biopharmaceutical research and development company. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The firm focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
Read More LadRx Corp (LADX) Chart
Key Statistics of LadRx Corp (LADX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.11Volume
204.00P/E Ratio (TTM)
0.1352 Week Range
Market Cap
51.98KAvg. Volume
243.67Dividend Yield
-Financial Metrics & Statements of LadRx Corp (LADX)
FAQ's for LadRx Corp (LADX)
- According to Musaffa’s Shariah screening methodology, LadRx Corp (LADX) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.